Arrowhead Pharmaceuticals, Inc. $ARWR Holdings Lessened by Privium Fund Management B.V.

Privium Fund Management B.V. cut its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 7.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 215,818 shares of the biotechnology company’s stock after selling 18,404 shares during the period. Arrowhead Pharmaceuticals comprises about 2.7% of Privium Fund Management B.V.’s holdings, making the stock its 12th largest holding. Privium Fund Management B.V. owned about 0.15% of Arrowhead Pharmaceuticals worth $14,125,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Arrowhead Pharmaceuticals during the 2nd quarter worth about $1,208,838,000. Siren L.L.C. boosted its stake in shares of Arrowhead Pharmaceuticals by 7.7% in the 1st quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company’s stock valued at $101,290,000 after buying an additional 115,000 shares during the period. Janus Henderson Group PLC grew its position in shares of Arrowhead Pharmaceuticals by 12.2% during the first quarter. Janus Henderson Group PLC now owns 1,436,990 shares of the biotechnology company’s stock worth $90,119,000 after buying an additional 156,544 shares in the last quarter. Jupiter Topco LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the second quarter worth about $99,623,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the first quarter worth approximately $64,988,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR traded up $0.70 during trading hours on Friday, reaching $58.16. The stock had a trading volume of 1,363,195 shares, compared to its average volume of 1,708,830. The firm has a market cap of $8.19 billion, a price-to-earnings ratio of -25.85 and a beta of 1.34. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $37.06 and a fifty-two week high of $95.49. The firm has a 50-day moving average of $66.91 and a 200-day moving average of $71.48.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The business had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. During the same period in the previous year, the firm earned ($1.26) earnings per share. The business’s revenue was up 171.0% compared to the same quarter last year. Equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.62 earnings per share for the current year.

Insider Activity

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 2,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the transaction, the director directly owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. The trade was a 5.95% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Michael S. Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the sale, the director directly owned 111,459 shares in the company, valued at approximately $9,730,370.70. The trade was a 9.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 3.60% of the company’s stock.

Analysts Set New Price Targets

ARWR has been the subject of several recent analyst reports. B. Riley Financial lifted their price objective on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Piper Sandler reissued an “overweight” rating and issued a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Citigroup started coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, September 8th. They issued a “buy” rating and a $108.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, August 17th. Finally, UBS Group initiated coverage on Arrowhead Pharmaceuticals in a report on Thursday, October 15th. They set a “buy” rating and a $109.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $99.07.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes using RNA interference (RNAi). The company’s proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi-based therapies to specific tissues and reduce the production of targeted proteins.

Arrowhead’s research and development programs address a range of conditions, including cardiometabolic, pulmonary, liver, and central nervous system diseases.